Commodore Capital LP Satsuma Pharmaceuticals, Inc. Transaction History

Commodore Capital LP

  • $1.12 Billion
  • Q2 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Feb 14, 2022
BUY
$4.15 - $6.24 $2.46 Million - $3.7 Million
592,525 Added 19.0%
3,711,286 $16.7 Million
Q3 2021

Nov 15, 2021
BUY
$4.54 - $7.17 $100,025 - $157,969
22,032 Added 0.71%
3,118,761 $14.5 Million
Q2 2021

Aug 16, 2021
BUY
$4.8 - $7.25 $3.19 Million - $4.82 Million
665,024 Added 27.35%
3,096,729 $21.8 Million
Q1 2021

May 17, 2021
BUY
$4.57 - $7.18 $11.1 Million - $17.5 Million
2,431,705 New
2,431,705 $14.4 Million

About Satsuma Pharmaceuticals, Inc.

STSA Quotes by TradingView
  • Ticker STSA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 31,587,500
  • Description
  • Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can ...
More about STSA
Track This Portfolio

Track Commodore Capital LP Portfolio

Follow Commodore Capital LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Commodore Capital LP, based on Form 13F filings with the SEC.

News

Stay updated on Commodore Capital LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email